Compare Ascendis Pharma A/S (ASND) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Williams-Sonoma, Inc. — how do they compare? Ascendis Pharma A/S trades at $254.76 (market cap $16.67B), while Williams-Sonoma, Inc. trades at $245.15 (market cap $29.51B). The key difference: Williams-Sonoma, Inc. is the larger of the two by market cap, and Williams-Sonoma, Inc. pays a 1.21% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | WSM | |
|---|---|---|
Market Cap | $16.67B | $29.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $251.81 |
52-Week Low | $189.74 | $168.64 |
Enterprise Value | $17.04B | $30.35B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
Williams-Sonoma (WSM) trades at $246.14, down 1.87% on the day, amid a generally bullish technical outlook. The stock shows strong profitability with a net income margin of 13.81% and has beaten earnings estimates for three consecutive quarters. Recent news highlights its digital-first transformation and competitive strength in home furnishings.
The outlook is supported by solid fundamentals and positive earnings momentum, but high valuation ratios and overbought RSI levels pose near-term risks. Analyst consensus is mixed, with a moderate buy rating but a price target below the current price, suggesting cautious optimism amid execution and consumer spending concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
